Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroendocrine Tumors 13Meningioma 6Paraganglioma 5Neuroblastoma 5Pheochromocytoma 4Carcinoid Tumor 4von Hippel-Lindau Disease 3Medulloblastoma 3Prostatic Neoplasms 2Oncogenic osteomalacia 2Neuroectodermal Tumors, Primitive 2Multiple Endocrine Neoplasia Type 1 2Gastro-enteropancreatic neuroendocrine tumor 2Tumor Positron-Emission Tomography 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Pinealoma 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroma, Acoustic 1Neoplasms, Neuroepithelial 1Neoplasms 1Multiple Endocrine Neoplasia 1Metastatic Neuroendocrine Prostate Cancer 1Kidney Neoplasms 1Hypoglycemia 1Hypertension 1Hyperparathyroidism 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × gallium Ga 68 dotatate × Clear all
NCT07284589 2026-04-08

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Nuclear Imaging Institute

Phase 2 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡